Targeted delivery of EV‐encapsulated PTX at a low dose (10‐20 times lower than the clinical‐equivalent dose) significantly enhanced the drug efficacy in suppressing tumour growth in an EGFR‐positive lung cancer xenografted mouse model. This evidence concerns the gene EGFR and neoplasm.